

NHS Kent & Medway Medicines Optimisation Group

Recent NICE publications – June 2023

FOR INFORMATION

NICE Publications

NICE clinical guidelines

[Head injury: assessment and early management published May 2023](#)

This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.

Updated NICE Clinical Guidelines

[Hypertension in pregnancy: diagnosis and management Updated April 2023](#)

This guideline covers diagnosing and managing hypertension (high blood pressure), including pre-eclampsia, during pregnancy, labour and birth. It also includes advice for women with hypertension who wish to conceive and women who have had a pregnancy complicated by hypertension. It aims to improve care during pregnancy, labour and birth for women and their babies. **In April 2023**, NICE updated recommendations on when to offer placental growth factor (PLGF)-based testing for pre-eclampsia, in line with our diagnostics guidance on PLGF-based testing for pre-eclampsia. See the update information for more details.

[Metastatic malignant disease of unknown primary origin in adults: diagnosis and management Updated April 2023](#)

This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person's condition. This guideline covers carcinomas only and does not cover, for example, lymphoma, melanoma and sarcoma. For other NICE guidelines on cancer, see the [cancer topic page](#).

In April 2023, NICE withdrew recommendations on gene-expression-based profiling and added a link to the [NHS Genomic Medicine Service's national genomic test directory](#).

[Diabetes \(type 1 and type 2\) in children and young people: diagnosis and management Updated May 2023](#)

This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.

In May 2023, NICE reviewed the evidence and made new recommendations on blood glucose monitoring and management for children and young people with type 2 diabetes. For more details, see the [update information](#).

[Acne vulgaris: management Updated May 2023](#)

This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.

In May 2023, NICE clarified [recommendations on oral isotretinoin treatment](#) in line with the [2020 MHRA reminder of important risks and precautions](#), and the [2023 MHRA advice on new safety measures to be introduced in the coming months](#) following the [April 2023 report of the Commission on Human Medicines Isotretinoin Expert Working Group](#).

[Cardiovascular disease: risk assessment and reduction, including lipid modification Updated May 2023](#)

This guideline covers the assessment and care of adults who are at risk of or who have cardiovascular disease (CVD), such as heart disease and stroke. It aims to help healthcare professionals identify people who are at risk of cardiovascular problems including people with type 1 or type 2 diabetes, or chronic kidney disease. It describes the lifestyle changes people can make and how statins can be used to reduce their risk.

This guideline does not cover people with familial hypercholesterolaemia (FH). For guidance on FH, see [NICE's guideline on familial hypercholesterolaemia: identification and management](#).

In **May 2023**, NICE reviewed the evidence and made new/updated recommendations on risk assessment tools for primary prevention of CVD, cardioprotective diets, and statin treatment for primary and secondary prevention of CVD. For further details, see the [update information](#).

[Atopic eczema in under 12s: diagnosis and management Updated May 2023](#)

This guideline covers diagnosing and managing atopic eczema in children under 12. It aims to improve care for children with atopic eczema by making detailed recommendations on treatment and specialist referral. The guideline also explains how healthcare professionals should assess the effect eczema has on quality of life, in addition to its physical severity. In **June 2023**, NICE reviewed the evidence on emollient bath additives and updated our [recommendations on emollients](#). For more details, see [update information](#).

NICE Quality Standards

No New NICE Quality Standards

Updated NICE Quality Standards

[Head injury Updated May 2023](#)

This quality standard covers assessment, early management and rehabilitation following head injury in adults, young people and children. It describes high-quality care in priority areas for improvement.

In **May 2023**, changes were made to align this quality standard with the updated [NICE guideline on head injury](#).

Statement 2 on CT head scans for people taking anticoagulants has been removed because the recommendations in this area have changed. See [update information](#) for more details.

[Cardiovascular risk assessment and lipid modification Updated May 2023](#)

This quality standard covers identifying and assessing cardiovascular risk in adults (aged 18 and over) and treatment to prevent cardiovascular disease. It describes high-quality care in priority areas for improvement.